In contrast, significant sVEGFR-1 upregulation could be confirmed in patients with more aggressive disease stages (P ≤ 0.009), but the upregulated sVEGFR-1 failed to suppress VEGF levels in these patients with stage III, IV; T3,4; N+ and high grade tumor (G3,4) (P ≤ 0.02). Here, VEGFA is linked to neoplasm.